Approved November 1998
Urology & Kidneys
Nonabsorbed, oral, phosphate binding polymer hydrogel for the control of hyperphosphatemia in patients with end stage renal disease.
The agent acts by binding phosphorus in the gastrointestinal tract and allows elimination of phosphorus through normal digestive processes.
The RenaGelRenagel (sevelamer hydrochloride) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.